Loading…
Loading…
News Release Highlights: U.S. FDA Pharmacy Compounding Advisory Committee recommends the inclusion of six peptide substances, including BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, on the FDA's 503A Bulks List, representing a significant step in the FDA's ongoing regulatory review process for these peptide substances. Vanta has established a strategic operating framework supporting its contemplated U.S. peptide platform, including telehealth-enabled commercialization, FDA-registered compounding pharmacy coordination, peptide manufacturing and fulfillment capabilities, and compliant payment processing infrastructure.
Motus GI (NASDAQ: MOTS ) stock is falling on Friday following a warning that the medical technology company is in danger of being delisted. Motus GI got a delisting notice from the Listing Qualifications Staff of the Nasdaq Exchange on April 5.
FORT LAUDERDALE, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today reported its financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.
PORTLAND, Ore.--(BUSINESS WIRE)--EndoSound™ Inc., a pioneering medical technology company dedicated to advancing patient care, is pleased to announce the appointment of Scott Aldrich Jr as Chief Executive Officer on February 1st, 2024. Mr Aldrich is joining EndoSound from MotusGI (Nasdaq: MOTS) where he served as Vice President of Commercial and Strategy. Stephen Steinberg MD will remain on the executive leadership team as Chief Medical Officer. Mr Aldrich brings operational and commercial lead.
FORT LAUDERDALE, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus” or “the Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that it has entered into a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant held by an institutional investor to purchase an aggregate of 2,933,334 shares of the Company's common stock for gross proceeds to the Company of approximately $2.7 million.
FORT LAUDERDALE, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (“the “Company”) (NASDAQ: MOTS), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent (patent # 11904085) titled, “Colon Cleaning System with Automatic Self-Purging Feature.”
FORT LAUDERDALE, Fla., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (“the Company”) (NASDAQ: MOTS), today announced that its special meeting of stockholders held on February 16, 2024 (the “Special Meeting”) was convened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposal described in the Company's definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”) on January 24, 2024 (the “Proxy Statement”).
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Lancaster Colony (LANC), On Holding (ONON), Rent the Runway (RENT), 5E Advanced Materials (FEAM) and Motus GI (MOTS).
No recent filings indexed.